First National Trust Co Sells 37,295 Shares of Bristol-Myers Squibb (NYSE:BMY)

First National Trust Co decreased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 14.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 212,507 shares of the biopharmaceutical company’s stock after selling 37,295 shares during the quarter. First National Trust Co’s holdings in Bristol-Myers Squibb were worth $10,904,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Northern Trust Corp lifted its stake in shares of Bristol-Myers Squibb by 5.8% in the third quarter. Northern Trust Corp now owns 25,292,711 shares of the biopharmaceutical company’s stock worth $1,467,989,000 after acquiring an additional 1,394,158 shares during the period. Invesco Ltd. lifted its position in shares of Bristol-Myers Squibb by 8.6% in the 3rd quarter. Invesco Ltd. now owns 15,606,587 shares of the biopharmaceutical company’s stock worth $905,806,000 after purchasing an additional 1,240,902 shares during the period. Pacer Advisors Inc. boosted its stake in shares of Bristol-Myers Squibb by 48.0% in the 4th quarter. Pacer Advisors Inc. now owns 7,830,948 shares of the biopharmaceutical company’s stock valued at $401,806,000 after purchasing an additional 2,540,360 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in Bristol-Myers Squibb by 3.2% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,594,092 shares of the biopharmaceutical company’s stock worth $287,033,000 after buying an additional 172,769 shares during the last quarter. Finally, Pzena Investment Management LLC lifted its holdings in Bristol-Myers Squibb by 13.8% in the third quarter. Pzena Investment Management LLC now owns 4,924,194 shares of the biopharmaceutical company’s stock valued at $285,800,000 after buying an additional 596,625 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Stock Up 0.7 %

Shares of NYSE:BMY traded up $0.29 during mid-day trading on Friday, hitting $43.99. 12,104,489 shares of the company traded hands, compared to its average volume of 14,314,010. The stock has a market cap of $89.17 billion, a P/E ratio of -14.19, a P/E/G ratio of 14.82 and a beta of 0.45. The stock has a 50-day moving average price of $50.37 and a two-hundred day moving average price of $50.74. Bristol-Myers Squibb has a 12-month low of $43.33 and a 12-month high of $69.10. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. During the same quarter in the prior year, the business posted $2.05 EPS. The business’s revenue was up 4.7% compared to the same quarter last year. On average, equities research analysts forecast that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were paid a $0.60 dividend. The ex-dividend date was Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.46%. Bristol-Myers Squibb’s payout ratio is presently -77.42%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Wells Fargo & Company boosted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. Finally, Barclays reduced their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.